Importantly, in most patients, additional genetic lesions are found in NUP98-NSD1+ AML cells of which activating FLT3-ITD mutations are by far the most prevalent, present in about 80% of the cases [57]. This evidence concerns the gene FLT3 and acute myeloid leukemia.